Trastuzumab plus Chemotherapy in Gastric Cancer Overexpressing HER-2 and EGFR: A Case Report

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Oncology Research and Treatment

• Publication date

  2011-01-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000323345PMID 21346384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

  2010cited by this paper
• The dual EGFR/HER‐2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN‐38

  2009cited by this paper
• Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

  2009cited by this paper
• Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.

  2009cited by this paper
• Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.

  2009cited by this paper
• Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

  2009cited by this paper
• Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

  2009cited by this paper
• Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer

  2008cited by this paper
• Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients

  2008cited by this paper
• EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

  2008cited by this paper
• Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

  2008cited by this paper
• The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.

  2008cited by this paper
• HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

  2008cited by this paper
• Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models

  2007cited by this paper
• Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients

  2007cited by this paper
• Epidermal growth factor receptor and c-erbB-2 contents in unresectable (UICC R1 or R2) gastric cancer.

  2003cited by this paper
• Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer

  2003cited by this paper
• Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy.

  1982cited by this paper
• Cancer of the stomach.

  1951cited by this paper

• Exploring Technical Features to Enhance Control in Videoconferencing Psychotherapy: Quantitative Study on Clinicians’ Perspectives

  2024cites this paper
• Efficacy and Safety of Trastuzumab-based Therapy in Combination with Different Chemotherapeutic Regimens in Advanced Esophagogastric Cancer – a Single Cancer-center Experience

  2014cites this paper
• Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells

  2014cites this paper
• Utilisation of Nanoparticle Technology in Cancer Chemoresistance

  2012cites this paper